1- Gastroenterologist, Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran 2- Specialist of Infectious Diseases, Antimicrobial Resistance Research Center, Tehran University of Medical Sciences, Tehran, Iran , m-talebitaher@tums.ac.ir 3- Resident of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (16994 Views)
Background: chronic hepatitis C infection is a major health problem in hemophilia patients. There is no enough evidence about the long term outcome and efficacy of treatment in these patients. The aim of this study was to evaluate the clinical, biochemical and virologic outcome of chronic hepatitis C treated with peginterferone alfa2-a and ribavirin in hemophilia patients during a five- year follow up. Materials and Methods: In a retrospective cohort study, 35 hemophilia patients with chronic HCV infection who were treated by peginterferon and ribavirin were studied. The efficacy of therapy was expressed as sustained virologic response (SVR: undetectable HCVRNA after six month of standard therapy). Association of efficacy of therapy and genotyping were analyzed by chi-square using SPSS ver.15 software. P<0.05 was considered statistically significant. Results: twenty seven patients (93.1%) achieved SVR, six patients did not respond. Follow up after 3 and 5years of treatment showed the same results. No evidence of virologic, biochemical and clinical relapse were detected. None of the patients were demonstrated hepatitis decompensation or hepatocellular carcinoma. Conclusion: It seems that sustained virologic response and the absence of clinical, virologic relapse after long term follow up (5 years) means the rescue from the fetal hepatitis infection.
Khaleghi S, Talebi Taher M, Ahi S. Long-term effects of peg-interferon alfa-2a and ribavirin in hemophilic patients with chronic hepatitis C. MEDICAL SCIENCES 2012; 22 (2) :157-162 URL: http://tmuj.iautmu.ac.ir/article-1-572-en.html